Stockscreener 앱 받기
2.90
3.65%
-0.11
시간 외 거래:
2.93
0.03
+1.03%
전일 마감가:
$3.01
열려 있는:
$2.9
하루 거래량:
893.66K
Relative Volume:
0.91
시가총액:
$500.64M
수익:
-
순이익/손실:
$-54.70M
주가수익비율:
-8.7879
EPS:
-0.33
순현금흐름:
$-51.36M
1주 성능:
+4.32%
1개월 성능:
+25.00%
6개월 성능:
-23.88%
1년 성능:
-39.46%
1일 변동 폭
$2.82
$3.00
1주일 범위
$2.68
$3.02
52주 변동 폭
$2.31
$5.34
사바라 Stock (SVRA) Company Profile
명칭
Savara Inc
전화
51285113796
주소
6836 BEE CAVE ROAD, AUSTIN, TX
SVRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
2.90 | 500.64M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
사바라 Stock (SVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-11-13 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-15 | 개시 | JMP Securities | Mkt Outperform |
| 2023-11-07 | 개시 | Guggenheim | Buy |
| 2023-05-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-31 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-03-16 | 개시 | Piper Sandler | Overweight |
| 2021-03-15 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-13 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | 재개 | ROTH Capital | Neutral |
| 2018-01-03 | 개시 | Ladenburg Thalmann | Buy |
| 2017-09-27 | 재개 | ROTH Capital | Buy |
| 2017-09-22 | 개시 | Jefferies | Buy |
| 2017-09-11 | 개시 | JMP Securities | Mkt Outperform |
모두보기
사바라 주식(SVRA)의 최신 뉴스
Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt? - simplywall.st
Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress - MSN
Savara Secures $200 Million Loan Agreement with Hercules Capital - MSN
Savara director David Ramsay acquires $416,250 in common stock By Investing.com - Investing.com Australia
Savara Insider Bought Shares Worth $416,250, According to a Recent SEC Filing - MarketScreener
Savara director David Ramsay acquires $416,250 in common stock - Investing.com India
Savara Completes BLA Submission for MOLBREEVI to Treat aPAP - MSN
Savara IncTerminates ATM Agreement With Evercore Effective April 2, 2025SEC Filing - MarketScreener
SAVARA Earnings Preview: Recent $SVRA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval By Investing.com - Investing.com Australia
Savara Inc ends sales agreement with Evercore - Investing.com
Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval - Investing.com India
Swiss National Bank Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
What is HC Wainwright’s Estimate for Savara Q1 Earnings? - Defense World
HC Wainwright Reaffirms Buy Rating for Savara (NASDAQ:SVRA) - Defense World
Savara enters loan and security agreement with Hercules Capital - MSN
Savara stock holds Buy rating, $6 target from H.C. Wainwright By Investing.com - Investing.com Australia
Savara stock holds Buy rating, $6 target from H.C. Wainwright - Investing.com India
Charles Schwab Investment Management Inc. Grows Position in Savara Inc (NASDAQ:SVRA) - Defense World
Nkarta to lay off 34% of staff; Savara’s debt financing deal - Endpoints News
Savara Inc. (SVRA) reports earnings - Quartz
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Joplin Globe
Breakthrough: Savara Advances First-Ever aPAP Treatment with FDA Filing, Reports $196M Cash Position - Stock Titan
JMP maintains $9 target on Savara stock, sees FDA nod By Investing.com - Investing.com South Africa
JMP maintains $9 target on Savara stock, sees FDA nod - Investing.com India
Savara secures $200M loan to support respiratory drug launch By Investing.com - Investing.com South Africa
Savara secures $200M loan to support respiratory drug launch - Investing.com India
Savara Gets Up to $200 Million Loan From Hercules Capital - Marketscreener.com
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital - Bluefield Daily Telegraph
Major Financial Boost: Savara Lands $200M Debt Deal as FDA Decision Approaches - Stock Titan
Savara submits FDA application for aPAP therapy MOLBREEVI - Investing.com
Savara Completes Submission Of The Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - MarketScreener
Breakthrough: First Treatment for Rare Lung Disease aPAP Heads to FDA Review - Stock Titan
Bank of New York Mellon Corp Purchases 17,870 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ: SVRA) Stock: Investors Need To Know This - Stocks Register
Victory Capital Management Inc. Reduces Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Savara Inc (NASDAQ:SVRA) Receives $8.83 Consensus Price Target from Analysts - Defense World
Savara Inc. to Present at Leerink Global Healthcare Conference - MSN
Breakthrough Phase 3 Results: New Treatment Reduces Lung Procedures in Rare Disease Patients - StockTitan
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN
Oppenheimer & Co. Inc. Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Rhumbline Advisers Purchases 9,041 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ: SVRA): An Enticing Stock To Watch - Stocks Register
사바라 (SVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):